-
公开(公告)号：US20190022243A1
公开(公告)日：2019-01-24
申请号：US16069395
申请日：2017-01-13
Applicant: GENMAB A/S
Inventor： Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
公开(公告)号：US20230087745A1
公开(公告)日：2023-03-23
申请号：US17821837
申请日：2022-08-24
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ , Edward VAN DEN BRINK , Dennis VERZIJL
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20230321261A1
公开(公告)日：2023-10-12
申请号：US17957302
申请日：2022-09-30
Applicant: GENMAB A/S
Inventor： Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61P35/00 , C07K16/2863 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
Patent Agency Ranking
公开(公告)号：US20200239579A1
公开(公告)日：2020-07-30
申请号：US16491464
申请日：2018-03-09
Applicant: GENMAB A/S
Inventor： Isil ALTINTAS , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rik RADEMAKER , Paul PARREN , Bart DE GOEIJ
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/42
Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20180326084A1
公开(公告)日：2018-11-15
申请号：US15742818
申请日：2016-07-08
Applicant: GENMAB A/S
Inventor： Julia BOSHUIZEN , Kirstine JACOBSEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Henrik Jørn DITZEL , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61K2039/505 , A61P35/00 , C07K16/2863 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
-
公开(公告)号：US20170355767A1
公开(公告)日：2017-12-14
申请号：US15541594
申请日：2016-01-08
Applicant: GENMAB A/S
Inventor： Patrick ENGELBERTS , Esther BREIJ , Rik RADEMAKER , Isil ALTINTAS , David SATIJN , Sandra VERPLOEGEN , Riemke VAN DIJKHUIZEN RADERSMA , Edward VAN DEN BRINK , Janine SCHUURMAN , Paul PARREN
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/2809 , A61K39/39558 , A61K2039/505 , C07K16/2887 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/90 , C07K2317/92 , C07K2317/94
Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
-
公开(公告)号：US20240317861A1
公开(公告)日：2024-09-26
申请号：US18539509
申请日：2023-12-14
Applicant: GENMAB A/S
Inventor： Isil ALTINTAS , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rik RADEMAKER , Paul PARREN , Bart DE GOEIJ
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/42
CPC classification number: C07K16/2827 , A61K39/3955 , A61K45/06 , A61P35/00 , C07K16/2809 , C07K16/4258 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20160168247A1
公开(公告)日：2016-06-16
申请号：US14902757
申请日：2014-07-04
Applicant: GENMAB A/S
Inventor： Edward VAN DEN BRINK , Joost J. NEIJSSEN , Aran Frank LABRIJN , Joyce MEESTERS , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
